Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11080501 | 1.00 | CA2 (0.45) | CA2CA12CA1CA9CHKA | |
| SCHEMBL20066172 | 0.92 | CA2 (0.47) | CA2CA12CA1CA9CHKA | |
| Pyridine SCHEMBL28122736 | 0.85 | SIGMAR1 (0.39) | CA2CA12CA1CA9CHKA | |
| SCHEMBL27656999 | 0.84 | — | — | |
| SCHEMBL25237838 | 0.84 | MAPT (0.41) | MAPTPOLBMEN1KMT2AGAA | |
| Trifluoroacetic Acid SCHEMBL23778408 | 0.82 | PKM (0.40) | CA2CA12CA1CA9CHKA | |
| Trifluoroacetic Acid SCHEMBL23778407 | 0.82 | PKM (0.40) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2872323 | 0.82 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL30333262 | 0.81 | CA2 (0.43) | CA2CA12CA1CA9CHKA | |
| SCHEMBL12417796 | 0.81 | CA2 (0.43) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707315-A1 | COPOLYMER, COMPOSITION AND USE THEREOF | Beijing Mapu New Materials Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| EP-4707315-A1 | COPOLYMER, COMPOSITION AND USE THEREOF | Beijing Mapu New Materials Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-4637926-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024245366-A1 | COPOLYMER, COMPOSITION AND USE THEREOF | 北京马普新材料有限公司 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-110462797-A | Polishing composition | FUJIMI INC | 2019-11-15 | — | — | CN | disclosed |
| CN-108026276-A | Polymerisable compound, polymeric compositions and their preparation and application | 3M创新有限公司 | 2018-05-11 | — | — | CN | disclosed |
| EP-2799435-B1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| CN-107001861-A | Two-part adhesive composition and the method for preparing adhesive composition | 3M创新有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-106133001-A | Compositions containing organo-borane and using method thereof | 3M创新有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-9187430-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| EP-2799435-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | Chengdu Di'ao Pharmaceutical Group Co. Ltd. (CN) | 2014-11-05 | — | — | EP | disclosed |
| US-8575144-B2 | Beta-lactamase inhibitory compounds | SOUTHERN METHODIST UNIVERSITY (US) | 2013-11-05 | — | — | US | disclosed |
| US-4426382-A | HYPOTENSIVE AGENTS | SANKYO COMPANY LIMITED (JP) | 1984-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | PARP1, PARP2, PARP11 | CA2 3658/4885CA12 3892/4885CA1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.